Polypharmacy and potential drug–drug interactions for people with HIV in the UK from the Climate‐HIV database
Authors:
Open Access
- 15 July 2020
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 21 (8) , 471-480
Abstract
Objectives: People with HIV (PWHIV) are likely to need therapies for comorbidities as they age. We assessed risk of drug–drug interactions (DDIs) in PWHIV.Methods: The Climate‐HIV electronic recording system was used to cross‐sectionally analyse records from PWHIV aged ≥ 18 years attending four UK HIV units with a current antiretroviral (ARV) prescription in February 2018. Antiretroviral and non‐ARV medications were categorized by clinical significance of DDIs (University of Liverpool DDI tool). Potential DDIs were predicted using treatment guidelines for commonly recorded comorbidities.Results: Among 4630 PWHIV (44% female), 41% were ≥ 50 years old. The average number of non‐ARV comedications increased from < 1 for patients aged ≤ 24 years to > 5 for patients aged ≥ 75 years; 65% were taking one or more non‐ARV comedications. The median (interquartile range) number of non‐ARVs was 1 (0–2) and 2 (1–5) for those aged < 50 and ≥ 50 years, respectively. Common comorbidities/concurrent health conditions occurred more frequently in patients aged ≥ 50 years vs. < 50 (53% vs. 34%). Boosted protease inhibitors were associated with the highest proportion of contraindicated comedications; dolutegravir and raltegravir had the fewest. For non‐ARVs, sildenafil and quetiapine were most likely to result in DDIs. Guideline‐recommended treatments for hepatitis C, hepatitis B, and tuberculosis had the highest proportions of contraindications when combined with ARV regimens, while treatments for hepatitis C, malignancy, and mental health conditions had the highest proportion of combinations potentially causing DDIs requiring dose monitoring or adjustment.Conclusions: Non‐ARV use by PWHIV is high and increases with age. Treatment decisions for ageing PWHIV should consider guideline recommendations for comorbidities.Keywords
Funding Information
- ViiV Healthcare
This publication has 17 references indexed in Scilit:
- Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelinesBMJ, 2015
- A cross-sectional, population-based study measuring comorbidity among people living with HIV in OntarioBMC Public Health, 2014
- The Next Therapeutic Challenge in HIV: PolypharmacyDrugs & Aging, 2013
- Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected PopulationJournal of General Internal Medicine, 2013
- A survey on polypharmacy and use of inappropriate medicationsToxicology International, 2012
- Medication Use and Functional Status Decline in Older Adults: A Narrative ReviewThe American Journal of Geriatric Pharmacotherapy, 2011
- Ageing with HIV: medication use and risk for potential drug-drug interactionsJournal of Antimicrobial Chemotherapy, 2011
- HIV and the body: a review of multidisciplinary managementHIV Medicine, 2010
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesThe Lancet, 2008
- Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkableExpert Opinion on Drug Safety, 2007